Current interest in targeting the NaPi2b protein in ovarian cancer by use of monoclonal antibodies either conjugated to alpha-emitting radionuclides [12–14], or as antibody drug conjugates [15] has highlighted the importance of evaluating the antigene expression in tumor samples. Here, SLC34A2 is linked to ovarian cancer.